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Summary
Background Lung volume reduction surgery improves survival in selected patients with emphysema, and has 
generated interest in bronchoscopic approaches that might achieve the same eﬀ ect with less morbidity and mortality. 
Previous trials with endobronchial valves have yielded modest group beneﬁ ts because when collateral ventilation is 
present it prevents lobar atelectasis.
Methods We did a single-centre, double-blind sham-controlled trial in patients with both heterogeneous emphysema 
and a target lobe with intact interlobar ﬁ ssures on CT of the thorax. We enrolled stable outpatients with chronic 
obstructive pulmonary disease who had a forced expiratory volume in 1 s (FEV1) of less than 50% predicted, signiﬁ cant 
hyperinﬂ ation (total lung capacity >100% and residual volume >150%), a restricted exercise capacity (6 min walking 
distance <450 m), and substantial breathlessness (MRC dyspnoea score ≥3). Participants were randomised (1:1) by 
computer-generated sequence to receive either valves placed to achieve unilateral lobar occlusion (bronchoscopic lung 
volume reduction) or a bronchoscopy with sham valve placement (control). Patients and researchers were masked to 
treatment allocation. The study was powered to detect a 15% improvement in the primary endpoint, the FEV1 
3 months after the procedure. Analysis was on an intention-to-treat basis. The trial is registered at controlled-trials.
com, ISRCTN04761234.
Findings 50 patients (62% male, FEV1 [% predicted] mean 31·7% [SD 10·2]) were enrolled to receive valves (n=25) 
or sham valve placement (control, n=25) between March 1, 2012, and Sept 30, 2013. In the bronchoscopic lung 
volume reduction group, FEV1 increased by a median 8·77% (IQR 2·27–35·85) versus 2·88% (0–8·51) in the 
control group (Mann-Whitney p=0·0326). There were two deaths in the bronchoscopic lung volume reduction 
group and one control patient was unable to attend for follow-up assessment because of a prolonged pneumothorax.
Interpretation Unilateral lobar occlusion with endobronchial valves in patients with heterogeneous emphysema and 
intact interlobar ﬁ ssures produces signiﬁ cant improvements in lung function. There is a risk of signiﬁ cant 
complications and further trials are needed that compare valve placement with lung volume reduction surgery.
Funding Eﬃ  cacy and Mechanism Evaluation Programme, funded by the Medical Research Council (MRC) and 
managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership.
Copyright © Davey et al. Open Access article distributed under the terms of CC BY.
Introduction
Despite optimal pharmacological therapy and pulmonary 
rehabilitation, many patients with chronic obstructive 
pulmonary disease (COPD) remain very disabled.1 In 
carefully selected patients with emphysema, lung volume 
reduction surgery (LVRS) to resect the worst aﬀ ected areas 
of lung has improved lung function, exercise capacity 
health status, and survival.2 However, this surgical inter-
vention is associated with substantial morbidity, and an 
early mortality rate of about 5% was reported in the 
National Emphysema Treatment Trial (NETT) trial,2 
although recent case series have reported lower rates.3 
Nevertheless, there is still reluctance to refer patients for 
LVRS,4 and there has been considerable interest in 
developing novel treatment approaches that can also reduce 
lung volumes and gas trapping, either more safely than 
LVRS, or else in patients for whom LVRS is not an option.5–11
One approach is placing endobronchial valves in the 
airways supplying the most emphysematous part of the 
lung using a ﬁ breoptic bronchoscope (ie, bronchoscopic 
lung volume reduction, BLVR). The valves allow air to 
leave but not enter the target lobe, causing it to collapse 
and thus reducing gas trapping. In heterogeneous 
disease this reduction allows the relatively healthier 
lung to function better by diverting air to more perfused 
areas and recruiting previously compressed alveoli. 
Initial pilot work by our group and others was 
encouraging, showing that valve placement could 
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reduce dynamic hyperinﬂ ation, improving exercise 
capacity in association with improvements in in-
spiratory capacity and gas transfer.7,10 Moreover, follow 
up of an early cohort showed that all patients in whom 
radiological atelectasis had occurred (n=5) were alive 
6 years after the procedure, whereas eight of the 
14 without radiological atelectasis had died7 raising the 
possibility that BLVR might, like LVRS, oﬀ er a survival 
advantage in appropriately selected patients.
The VENT study compared unilateral endobronchial 
valve placement (n=220) with standard medical care 
(n=101).5 The protocol did not mask the patients or 
assessors to the allocation of treatment and no sham 
procedures were done. The study showed statistically but 
not clinically signiﬁ cant mean diﬀ erences in forced 
expiratory volume in 1 s (FEV1; 6·85%) and 6 min walking 
distance (5·7%) between BLVR and control groups 
at 6 months. This small eﬀ ect size was considered 
insuﬃ  cient for Federal and Drug Administration 
approval. A post hoc analysis identiﬁ ed a subgroup of 
responders: patients with high heterogeneity and intact 
interlobar ﬁ ssures who had a much bigger response with 
a mean 17·9% improvement in FEV1 seen if ﬁ ssures 
were intact compared with 2·8% if ﬁ ssures were 
incomplete. Additionally, patients with the greatest 
degree of heterogeneity on CT had signiﬁ cantly greater 
improvement in both FEV1 and 6 min walking distance.
Based on these data and evidence for a survival beneﬁ t 
where radiological atelectasis occurred,7 we did a 
randomised, double-blind sham-controlled trial of 
endobronchial valve placement in patients with COPD 
(the Bronchoscopic Lung Volume Reduction for patients 
with Heterogeneous emphysema and Intact Fissures 
study [BeLieVeR-HIFi]). We hypo thesised that valve 
placement would lead to a signiﬁ cant improvement in 
lung function, exercise capacity, and health status.
Methods
Study design and participants
The BeLieVeR-HIFi study was a randomised, parallel 
group, double-blind sham bronchoscopy controlled trial 
of unilateral, endobronchial valve placement (Zephyr 
valves; PulmonX, Redwood City, CA, USA) aimed to 
achieve lobar occlusion in patients with heterogeneous 
emphysema and intact interlobar ﬁ ssures. Participants 
were recruited between March 1, 2012, and Sept 30, 2013.
We enrolled stable outpatients with COPD who met the 
following criteria: FEV1 of less than 50% predicted; 
signiﬁ cant hyperinﬂ ation (total lung capacity >100% and 
residual volume >150%); a restricted exercise capacity 
(6 min walking distance <450 m) and substantial 
breathlessness (MRC dyspnoea score ≥3). Participants 
were all ex-smokers and on optimum medical therapy, 
including combined inhaled corticosteroids, long-acting 
β2 agonist, and anti-cholinergic agents unless they were 
intolerant or declined to use them. Patients were 
identiﬁ ed through a multidisciplinary COPD team 
meeting including chest physicians, surgeons, and 
radiologists. For inclusion, a CT scan of their thorax had 
to show heterogeneous emphysema with a deﬁ ned target 
lobe with lung destruction and intact adjacent interlobar 
ﬁ ssures. Scans were reviewed by two radiologists 
independently and a third adjudicated on any dis-
agreements. Radiologists had to agree that the worst 
aﬀ ected lobe of the lung had an emphysema score of 
more than 2 on the NETT study scoring system2 and that 
it scored at least 1 point higher than ipsilateral lobes and 
had more than 90% intact oblique ﬁ ssures visible. 
All (n=50) BLVR (n=25) Control (n=25)
Age (years) 62·8 (7·4) 62·3 (7·0) 63·3 (7·9)
Male (%) 31 (62%) 17 (68%) 14 (56%)
BMI (kg/m2) 24·5 (4·8) 24·5 (5·1) 24·5 (4·6)
Pack year smoking 
history
54 (24) 56 (26) 51 (23)
Exacerbation rate 
per year
3 (3) 3 (3) 3 (2)
FEV1 (L) 0·89 (0·32) 0·93 (0·35) 0·85 (0·30)
FEV1 (% predicted) 31·7 (10·2) 31·6 (10·2) 31·8 (10·5)
TLC (% predicted) 137 (14) 132 (12) 143 (15)
Residual volume 
(% predicted)
232 (43) 219 (39) 245 (44)
RV/TLC (%) 62·14 (8·12) 60·23 (8·06) 64·06 (7·88)
TLCO (% predicted) 33·8 (9·9) 33·8 (10·8) 33·7 (9·0)
KCO (% predicted) 45·4 (12·1) 45·8 (12·8) 45·1 (11·7)
PaCO₂ (kPa) 4·85 (0·73) 4·81 (0·86) 4·90 (0·61)
PaO₂ (kPa) 9·60 (1·20) 9·74 (1·45) 9·47 (0·89)
MRC dyspnoea 
score
4 (1) 4 (1) 4 (1)
CAT 25 (5) 24 (5) 27 (5)
SGRQc 
(symptoms)
71·23 (16·29) 68·49 (15·78) 73·97 (16·65)
SGRQc (activity) 88·35 (11·86) 86·41 (13·51) 90·29 (9·85)
SGRQc (impact) 57·14 (16·26) 56·47 (16·92) 57·81 (15·89)
SGRQc (total) 69·22 (12·78) 67·79 (13·17) 70·65 (12·48)
6MWD (m) 338 (87) 342 (94) 334 (81)
Peak workload 
(W)
23 25 21
Peak VO₂ (L/min) 0·89 0·93 0·86
Peak VCO₂ (L/min) 0·84 0·90 0·77
Peak VE (L/min) 41·12 (12·76) 41·84 (12·58) 40·40 (13·15)
Peak VE (% 
predicted)
41 42 40
TLIM (s) 305 (169) 306 (166) 305 (175)
Data are n (%) or mean (SD). BLVR=bronchoscopic lung volume reduction. 
BMI=body-mass index. FEV1=forced expiratory volume in 1 s. TLC=total lung 
capacity. RV=residual volume. TLCO=carbon monoxide transfer factor. KCO=carbon 
monoxide transfer coeﬃ  cient. PaCO2=arterial partial pressure of CO2. 
PaO2=arterial partial pressure of O2. MRC=Medical Research Council. CAT=chronic 
obstructive pulmonary disease (COPD) assessment test score. SGRQc=St George’s 
respiratory questionnaire for COPD. 6MWD=6 min walking distance. 
Workload=results of incremental cycle ergometry. VO2=oxygen consumption. 
VCO2=CO2 production. VE=minute ventilation. TLIM=endurance time on cycle 
ergometry at 70% of peak workload. 
Table 1: Baseline characteristics of study participants
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Patients were excluded if they had substantial comorbidity 
restricting their exercise capacity or prognosis; sub-
stantial daily sputum production; or hypoxia (ie, PaO₂ 
<6·5 Pa breathing air). Lower limits for lung function 
were not otherwise formally deﬁ ned but patients were 
excluded if they were considered clinically to be too 
restricted or frail to undergo bronchoscopy or to tolerate 
a pneumothorax.
The study was approved by the London—Bentham 
Research Ethics Committee (REC number 11/LO/1608); 
the sponsor was Imperial College, London. There was a 
trial steering group and an independent data monitoring 
committee. All patients provided written informed consent.
Randomisation and masking
We randomly assigned patients (1:1) to either BLVR or 
control groups using predetermined block randomisation, 
with a block size of 10, computer-generated by the trial 
statistician (WB). The allocation was obtained by 
telephone link from the bronchoscopy suite to the Clinical 
Trials Unit at the Royal Brompton Hospital once the 
patient had been sedated. Masking was maintained by 
having two separate teams: one which undertook the 
randomised procedures (PLS, ZZ, WHM) and a separate 
team, masked to study assignment, responsible for 
recruitment and the assessments (CD, MIP, NSH), as 
previously used in trials of bronchoscopic therapies for 
emphysema.10 Thus, both patients and the researchers 
assessing outcomes were masked to treatment allocation.
Procedures
The procedures took place within 2 weeks of the baseline 
assessment visit. Study participants underwent either 
unilateral lobar endobronchial valve placement aiming to 
achieve lobar atelectasis (BLVR group), or bronchoscopy 
and sham valve placement (control group). All procedures 
were done in the bronchoscopy suite at the Royal 
Brompton Hospital using moderate sedation with 
midazolam and alfentanyl. Procedures were done by a 
single operator (PLS) with an expertise in interventional 
bronchoscopy who had done more than 50 endobronchial 
valve procedures before study commencement.
Although target lobe selection was based on CT 
appearance alone, measurements of collateral ventilation 
using the Chartis (PulmonX, Redwood City, CA, USA) 
balloon catheter system were made in all participants so 
that the accuracy of the two approaches could be 
compared.12 Endobronchial valves were placed to occlude 
segmental bronchi leading to the target lobe (irrespective 
of the Chartis results). All procedures were unilateral. 
All patients underwent a chest radiograph after the 
procedure to check for the presence of a pneumothorax, 
which was reviewed by the treatment team only. If this 
was satisfactory they were then discharged home. Patients 
were counselled and provided with a post-procedure 
information sheet, irrespective of treatment allocation, 
giving advice on seeking medical attention in the presence 
of chest pain or sudden breathlessness, and providing 
advice for medical staﬀ  if the patient presented as an 
emergency.
Baseline and 3 month follow-up visits were done by an 
assessment team masked to treatment allocation. 
Spirometry, gas transfer, and lung volumes assessed 
by body plethysmography were measured with a 
CompactLab system (Jaeger, Hoechberg, Germany).13 
Lung function tests were all done after bronchodilator 
use. Predicted values used were those of the European 
Coal and Steel Community.14,15 Patients underwent 
endurance cycle ergometry with metabolic measurements 
at 70% of their maximum workload determined on an 
initial incremental test. Inspiratory capacity manoeuvres 
were done to track changes in dynamic hyperinﬂ ation 
assessed as end-expiratory lung volume. Patients also 
completed a 6 min walking test done according to 
American Thoracic Society guidelines on a 30 m course.16 
Health-related quality of life was assessed using 
the St George’s respiratory questionnaire for COPD 
(SGRQc)17 and COPD assessment test (CAT).18,19 Target 
lobe volume change was assessed by a radiologist (DHC) 
as an explicatory variable and scored as follows: 0, no 
change; 1, some volume loss (ﬁ ssures shift); 2, segmental 
atelectasis (band of collapsed lung); 3, complete 
atelectasis (complete collapse).
Figure 1: Trial proﬁ le
6MWD=6 min walking distance. PFTs=pulmonary function tests. COPD=chronic obstructive pulmonary disease.
104 patients assessed for eligibility
54 excluded 
35 did not meet inclusion criteria 
28 on CT
3 on 6MWD
3 on PFTs
1 had significant comorbidity
10 declined to participate
9 for other reasons
4 unable to contact
3 treated locally
2 died
50 patients randomly assigned
25 received bronchoscopic lung volume reduction 
with endobronchial valves
25 received bronchoscopy and sham valve 
placement (control)
2 lost to follow-up
1 died after removal of valves and 
respiratory failure
1 died after COPD with cor pulmonale
1 lost to follow-up (too unwell to attend follow-up)
25 analysed
24 baseline and follow-up data
1 baseline measurement used as follow-up 
measurement
25 analysed
23 had baseline and follow-up data 
2 values imputed
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Outcomes
The primary endpoint was the between group diﬀ erence 
in the percentage change in FEV1 measured 3 months 
after the procedure. Secondary endpoints were: change 
in endurance time (TLIM) on cycle ergometry at 70% of 
maximum achieved workload and changes in end 
expiratory lung volume at isotime; change in 6 min 
walking distance; and changes in health status (scores on 
the CAT and SGRQc).
Statistical analysis
Sample size calculation was based on the results in the 
VENT study subgroup in which complete lobar occlusion 
was achieved.5 This group had a mean 20·6% (SD 25·1) 
improvement in FEV1 at 6 months compared with a 
2·5% (2·5) fall in the control group. We considered an 
absolute diﬀ erence in response between the two groups 
of 15% to be clinically signiﬁ cant. An 80% power and a 
signiﬁ cance level of 0·05 needed 21 patients in each 
group assuming that the mean change in FEV1 from 
baseline in the control group was 0% (2·5) and the mean 
change in the group receiving BLVR was 15% (25). 
50 patients were recruited to allow a 20% drop-out rate.
Data were entered into an electronic database developed 
by The Imperial College Clinical Trials Unit using InForm 
(Oracle, Reading, UK), and analysis was done by the trial 
statistician (WB) using Stata version 12 and SAS version 
9.3 (SAS Institute Inc., Cary, NC, USA). Analysis was on 
an intention-to-treat basis as pre-speciﬁ ed in a formal 
statistical analysis plan. Categorical data are presented as 
percentages and comparisons done using the Pearson χ² 
test. Normally distributed numeric data are presented as 
mean with SD or 95% CI. Non-normally distributed 
numeric data are presented as median (IQR). Because 
responses were skewed, Mann-Whitney testing was used 
to test whether the response to BLVR treatment was better 
than placebo. A post hoc univariate analysis of factors 
associated with change in cycle endurance time using 
regression with cluster option (ie, taking into account the 
paired nature of the data and relaxing the conditions for 
independence) was done. A p value of less than 0·05 
indicated statistical signiﬁ cance. Missing data were 
imputed using the Markov chain Monte Carlo method, 
which creates multiple imputations by using simulations 
from a Bayesian prediction distribution. For responder 
analyses, minimum clinically important diﬀ erences were 
pre-speciﬁ ed as a 15% increase for FEV1, 350 mL reduction 
in the residual volume,20 4 point decrease on the SGRQc 
scale,17,21 2 point decrease on the CAT scale,19,22 an increase 
of 105 s for endurance cycle TLIM,23 and an increase of 26 m 
in 6 min walking distance.24 The trial is registered at 
controlled-trials.com, ISRCTN04761234. The protocol has 
been published elsewhere.25
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
BLVR Control p value
ΔFEV1 (%) 8·77% (2·27 to 35·85) 2·88% (0 to 8·51) 0·0326
ΔFEV1 (L) 0·06 (0·02 to 0·38) 0·03 (0 to 0·06) 0·0273
ΔVC (%) 3·75% (–1·02 to 9·95) 0·84% (–7·14 to 6·57) 0·1370
ΔFEV1/VC 6·60 (2·61 to 23·04) 0·75 (–4·96 to 9·52) 0·0293
ΔTLC (%) –3·38% (–7·88 to 1·05) –1·57% (–3·09 to 0·89) 0·0448
ΔTLC (L) –0·32 (–0·70 to –0·06) –0·10 (–0·24 to –0·00) 0·0603
ΔRV (%) –6·58% (–18·60 to 2·94) –2·06% (–6·51 to 1·24) 0·0592
ΔRV (L) –0·26 (–1·07 to –0·16) –0·08 (–0·39 to –0·08) 0·0798
ΔRV/TLC –3·95 (–8·32 to 0·66) –1·20 (–2·46 to 1·28) 0·0715
ΔFRC (%) –5·81% (–15·71 to 0·89) 0·97% (–2·25 to 3·31) 0·0119
ΔFRC (L) –0·24 (–1·14 to 0·06) 0·07 (–0·15 to 0·20) 0·0213
ΔTLCO (mmol/min per kPa) 0·30 (0·03 to 0·43) 0 (–0·19 to 0·13) 0·0029
ΔKCO (mmol/min per kPa per L) 0·05 (0·01 to 0·11) 0·01 (–0·03 to 0·06) 0·0130
ΔMRC dyspnoea score 0 (–1 to 0) 0 (–1 to 0) 0·4037
ΔCAT (points) –2 (–7 to 3) 0 (–2 to 2) 0·2269
ΔSGRQc total (points) –4·40 (–16·93 to 6·76) –3·57 (–7·67 to 2·55) 0·3454
Δ6MWD (m) 25 (7 to 64) 3 (–14 to 20) 0·0119
Data are median (IQR). p values are for Mann-Whitney test. BLVR=bronchoscopic lung volume reduction. FEV1=forced 
expiratory volume in 1 s. VC=vital capacity. TLC=total lung capacity. RV=residual volume. FRC=functional residual 
capacity. TLCO=carbon monoxide transfer factor. KCO=carbon monoxide transfer coeﬃ  cient. CAT=chronic obstructive 
pulmonary disease (COPD) assessment test score. SQRGc=St George’s respiratory questionnaire for COPD. 
6MWD=6 min walking distance.
Table 2: Change in outcome measures from baseline to 3 months
Figure 2: Change in forced expiratory volume in 1 s (FEV1) at 3 months in 
patients treated with bronchoscopic lung volume reduction with 
endobronchial valves compared with controls who underwent sham treatment
Bars are mean and 95% CIs. Red symbols represent the four patients who had 
collateral ventilation detected using the Chartis system and were treated with 
bronchoscopic lung volume reduction.
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Results
The baseline characteristics of the 50 enrolled patients 
with COPD are shown in table 1 and more fully in the 
appendix. BLVR and control groups were generally well 
matched, but percent predicted residual volume and 
total lung capacity were higher in the control group. The 
trial proﬁ le describing patient ﬂ ow through the study is 
shown in ﬁ gure 1. The median number of valves placed 
per patient was 3 (range 1–6). There were two deaths in 
the BLVR group and one control patient was unable to 
attend for follow-up assessment because of a prolonged 
pneumothorax; 3 month data were available for 
23 patients receiving BLVR and 24 controls.
Response to treatment was assessed at 3 months 
(mean [SD] 93 [12] days; table 2, ﬁ gure 2, and appendix). 
FEV1 increased by a mean 24·8% (95% CI 8·0–41·5) 
from baseline in the BLVR group and 3·9% (0·7–7·1) in 
controls. However, the response in the BLVR group was 
heavily skewed so non-parametric tests were used for 
analysis. Median (IQR) FEV1 changes at 3 months were 
8·77% (2·27–35·85) in the BLVR group and 2·88% 
(0–8·51) in controls (Mann-Whitney p=0·0326; table 2). 
The BLVR group also had a signiﬁ cant improvement in 
6 min walking distance and TLIM on cycle ergometry 
(tables 2 and 3). This result was accompanied by 
signiﬁ cant improvements in lung volumes and gas 
transfer. CAT and SGRQc scores improved more in the 
BLVR group but compared with the control group were 
not statistically signiﬁ cant. Improvement in FEV1 was 
not associated with any baseline variable (appendix).
In univariate analysis, improvement in cycle ergometry 
TLIM was associated with improvements in spirometry, 
lung volumes, and gas transfer, and reductions in dynamic 
lung volumes, respiratory rate, and breath lessness during 
exercise (table 4). In multivariate analysis, an increase in 
FEV1 was retained, together with a fall in isotime 
respiratory rate and Borg dyspnoea score, as factors 
associated with improvement in TLIM (r²=0·59, p<0·0001). 
In the BLVR group, eight patients were scored as having 
“complete collapse” of the target lobe, ﬁ ve “a band of 
atelectasis”, two “some volume loss”, and eight no change.
Four treated patients, despite having ﬁ ssures scored as 
intact on CT as a criterion for study entry, had collateral 
ventilation detected by the Chartis system (collateral 
ventilation positive). Table 5 compares response rates 
between controls and the whole BLVR group and the 
BLVR group with collateral ventilation positive patients 
excluded. Of note, it was not possible to determine 
collateral ventilation in six (12%) patients with the Chartis 
system, consistent with a previous study reporting a 7% 
failure rate.26
Individual patient responses to treatment are shown in 
the appendix, including both absolute values and 
numbers achieving the minimum clinically important 
diﬀ erences for the various variables measured. These 
data also show the lobe targeted and whether collateral 
ventilation was detected by the Chartis system.
Two patients in the BLVR group died within 90 days of 
the procedure (table 6). The ﬁ rst developed a cough and a 
decision was taken to remove the valves 49 days after they 
had been placed. At the time of removal, which was 
diﬃ  cult, he developed a tension pneumothorax with an 
ongoing signiﬁ cant air leak. He progressed to respiratory 
See Online for appendix
BLVR Control p value
TLIM (s) 25 (–53 to 302) –10·8 (–69 to 33) 0·0256
Isotime
EELV (L) –0·35 (–1·16 to –0·07) 0·01 (–0·27 to 0·26) 0·0060
IRV (L) 0·04 (–0·04 to 0·25) –0·09 (–0·38 to 0·14) 0·0434
VE (L/min) 0·14 (–2·45 to 2·83) 0·83 (–1·76 to 2·76) 0·4074
RR (/min) 0 (–10 to 1) 0 (–2 to 4) 0·1223
Vt (mL) 32·60 (25·96 to 40·30) 27·29 (22·28 to 33·66) 0·0369
Borg leg discomfort 0 (–1 to 1) 0 (–1 to 1) 0·2692
Borg breathlessness 0 (–2 to 0) 0 (–1 to 2) 0·0800
Peak
EELV (L) –0·33 (–1·06 to –0·04) –0·01 (–0·26 to 0·19) 0·0059
IRV (L) 0·09 (–0·09 to 0·35) –0·085 (–0·315 to 0·115) 0·0233
VE (L/min) –0·18 (–2·16 to 5·23) –0·55 (–1·93 to 2·84) 0·4577
RR (/min) –1 (–5 to 2) –1 (–3 to 4) 0·1478
Vt (mL) 33·82 (26·48 to 40·28) 28·05 (22·25 to 35·29) 0·0306
Borg leg discomfort 0 (–1 to 1) 0 (–1 to 0) 0·3086
Borg breathlessness 0 (–1 to 1) 0 (–1 to 1) 0·4451
Data are median (IQR). p values are for Mann-Whitney test. BLVR=bronchoscopic lung volume reduction. 
TLIM=endurance time at 70% peak workload. EELV=end expiratory lung volume. IRV=inspiratory reserve volume. 
VE=minute ventilation. RR=respiratory rate. Vt=tidal volume.
Table 3: Change in exercise variables from baseline to 3 month follow-up
Univariate regression Multiple stepwise regression
β (95% CI) r² p value β (95% CI) r² p value
ΔFEV₁ 7·18 (2·29 to 12·07) 0·60 0·005 3·24 (1·64 to 4·85) <0·0001
ΔVC 3·97 (1·03 to 6·90) 0·60 0·009 ·· ·· ··
ΔTLCO 2·76 (0·88 to 4·64) 0·57 0·005 ·· ·· ··
ΔTLC –1·84 (–3·98 to 0·30) 0·54 0·090 ·· ·· ··
ΔRV –2·83 (–4·55 to –1·10) 0·61 0·002 ·· ·· ··
ΔIC (at rest) 4·32 (1·92 to 6·73) 0·62 0·001 ·· ·· ··
ΔEELV (isotime) –2·50 (–3·88 to –1·12) 0·61 0·001 ·· ·· ··
ΔIRV (isotime) 3·97 (0·63 to 7·32) 0·57 0·021 ·· ·· ··
ΔVT (isotime) 8·06 (1·43 to 14·68) 0·60 0·018 ·· ·· ··
ΔRR (isotime) –0·29 (–0·45 to –0·14) 0·63 0·000 –0·07 (–0·14 to –0·006) 0·59 0·033
ΔBorg dyspnoea 
score (isotime)
–0·69 (–1·08 to 0·30) 0·58 0·001 –0·26 (–0·49 to –0·02) ·· 0·032
ΔBorg leg 
discomfort 
score (isotime)
–0·04 (–0·60 to 0·68) 0·51 0·90 ·· ·· ··
Univariate analysis of factors associated with change in cycle endurance time using regression with cluster option (ie, 
taking into account the paired nature of the data and relaxing the conditions for independence). Factors with a p<0·05 
in univariate analysis were entered into multiple regression analysis. ΔFEV₁, ΔRR (isotime), and ΔBorg dyspnoea score 
(isotime) explained 59% of the variance in change in cycle endurance time. FEV1=forced expiratory volume in 1 s. 
VC=vital capacity. TLCO=carbon monoxide transfer factor. TLC=total lung capacity. RV=residual volume. IC=inspiratory 
capacity. EELV=end expiratory lung volume. IRV=inspiratory reserve volume. Vt=tidal volume. RR=respiratory rate.
Table 4: Factors associated with change in cycle endurance time at 3 months 
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failure, dying 17 days later despite intensive care 
treatment including endotracheal tube intubation and 
use of arteriovenous extracorporeal CO2 removal. 
The second patient died suddenly 3 days after valve 
placement. He underwent a post mortem; there was no 
evidence of pneumonia or pneumothorax and a diagnosis 
of death due to COPD with cor pulmonale was made. 
One patient in the control group was too unwell to attend 
for follow-up because of a spontaneous pneumothorax 
with prolonged air leak with onset 66 days after his sham 
bronchoscopy. Additionally, two patients in the BLVR 
group had pneumothoraces which both responded to 
intercostal tube drainage, one at 3 days and one at 12 days 
after the procedure. Four patients expectorated a valve 
before 3 months. These were replaced in three of 
four individuals before their follow-up visit. The patients 
were instructed not to inform the assessment team of 
these additional procedures.
Discussion
Placement of endobronchial valves in patients with 
severe COPD who have heterogeneous emphysema and 
intact interlobar ﬁ ssures on CT scan was associated with 
improvements in lung function and exercise capacity. 
This prospective, double-blind, randomised, controlled 
trial is the ﬁ rst study of bronchoscopic treatment to 
achieve this, through the use of an appropriately stratiﬁ ed 
approach to target a responder emphysema phenotype 
(panel). Our data suggest that in appropriately selected 
patients, endobronchial valve placement results in 
improvements in lung function which are of a similar 
order of magnitude to those seen with LVRS.2,3,27 The 
improvement in gas transfer is important because this is 
the lung function variable most strongly associated with 
survival in people with COPD.13 Previous trials such as 
VENT included many patients with collateral ventilation 
who therefore derived less beneﬁ t, in particular less lobar 
atelectasis, which is a key determinant of eﬀ ectiveness 
associated with improved lung function response5,8 and 
survival.7 Prospectively stratifying in favour of patients 
with heterogeneous disease and radiologically intact 
ﬁ ssures substantially increased the response rate.
The success rate of valve placement was higher than in 
previous studies because only patients with intact 
interlobar ﬁ ssures on CT were included; however, there 
were cases of positive collateral ventilation when assessed 
using the Chartis system. These cases were associated 
with no beneﬁ t from treatment raising the possibility of 
an additive role in improving patient selection. The 
Chartis system adds cost and time to procedures and its 
use cannot necessarily be recommended based on 
the present data. Furthermore, satisfactory Chartis 
measurements were not always possible for technical 
reasons (about 10%), a ﬁ nding consistent with previous 
studies.26 We acknowledge that the positive and negative 
predictive power of collateral ventilation measured with 
the Chartis system will vary depending on the CT criteria 
and method of ﬁ ssure analysis used in the initial selection 
strategy because this will aﬀ ect the pre-test probability of 
collateral ventilation. The ideal strategy for selecting 
patients in whom lobar exclusion can be achieved needs 
to be deﬁ ned and will remain unclear as reﬁ nements in 
technology and CT scoring of ﬁ ssure integrity evolve.
A key issue is the safety of this treatment approach. 
Spontaneous pneumothorax can occur when valve 
placement leads to a change in the conformation of the 
lung and can be a marker of eﬀ ective lobar occlusion. 
Therefore, as patient selection improves an increase in the 
BLVR Control 
(n=24)
p value*
All (n=23) CV-positive 
excluded 
(n=19)
FEV1 9 (39%) ·· 1 (4%) 0·0044
>15% improvement ·· 9 (47%) 1 (4%) 0·0022
RV 11 (48%) ·· 7 (29%) 0·24
0·35 L reduction20 ·· 11 (58%) 7 (29%) 0·07
6MWD 12 (52%) ·· 4 (17%) 0·012
26 m improvement24 ·· 12 (63%) 4 (17%) 0·004
Endurance cycle time 10 (43%) ·· 2 (8%) 0·008
105 s improvement23 ·· 9 (47%) 2 (8%) 0·005
SGRQc 11 (48%) ·· 11 (46%) 1·0
4 points reduction21 ·· 11 (58%) 11 (46%) 0·5
CAT 13 (57%) ·· 7 (29%) 0·080
2 points reduction22 ·· 13 (68%) 7 (29%) 0·015
Data are n (%). CV-positive=collateral ventilation using Chartis system. 
BLVR=bronchoscopic lung volume reduction. FEV1=forced expiratory volume in 
1 s. RV=residual volume. 6MWD=6 min walking distance. SGRQc=St George’s 
respiratory questionnaire for chronic obstructive pulmonary disease (COPD). 
CAT=COPD assessment test score. *Fisher’s exact test (this analysis does not 
include imputed values).
Table 5: Responder rates according to lung function, health status, and 
exercise criteria
BLVR (n=25) Control (n=25) p value
Events Patients Events Patients
Exacerbation (total) 23 16 22 20 0·42*, 0·35†
Of which required hospitalisation 5 ·· 3 ·· 0·70
Pneumonia (respiratory tract infection 
with radiograph changes)
2 2 0 0 0·49
Pneumothorax 2 2 1 1 1·0
Deaths 2 ·· 0 ·· 0·49
Respiratory failure 1 ·· 0 ·· 1·0
COPD with cor pulmonale 1 ·· 0 ·· 1·0
Expectorated valve 5 4 0 0 ··
Removal of valves 2 2 0 0 ··
Seizure (unrelated) 0 0 1 1 1·0
p value is for χ² test. BLVR=bronchoscopic lung volume reduction. COPD=chronic obstructive pulmonary disease. 
*Comparison of patients. †Comparison of events.
Table 6: Adverse events
Articles
1072 www.thelancet.com   Vol 386   September 12, 2015
pneumothorax rate is inevitable. In the present study 
pneumothorax occurred in two treated patients (8%) 
and in one control patient (4%). The management of 
pneumothorax in this context is conventional, usually 
with intercostal tube drainage. However, it is important 
that patients are selected who are considered likely to be 
able to withstand the associated acute lung function 
impairment a pneumothorax will cause. In part, 
bronchoscopic treatment for emphysema has been 
developed for people considered to be too disabled to 
withstand LVRS, but caution is needed given the 
pneumothorax risk. There were two deaths in the BLVR 
group. One occurred as a complication of valve removal, 
which was diﬃ  cult. Therefore, if valves need to be 
removed this should be done with limited force and if the 
valve cannot be removed easily a more controlled approach 
via rigid bronchoscopy should be considered. A rigid 
bronchoscopy approach might also be appropriate where 
there is signiﬁ cant granulation tissue or where the valve is 
at an acute angle. Because rigid bronchoscopy tends to be 
done by surgeons rather than physicians, this emphasises 
the importance of close liaison with thoracic surgery in 
the approach to the management of these patients.
A strength of the study was the masking of patients 
and assessors. The presence of a sham bronchoscopy 
meant that a more conﬁ dent estimate could be made of 
changes in health status that have often been large in 
unmasked studies, even in the absence of signiﬁ cant 
changes in lung function.28 The assessment of collateral 
ventilation in all participants using the Chartis system 
meant that control patients also underwent a procedure, 
which reinforced masking. Although patients in whom a 
pneumothorax occurred or who expectorated a valve 
were unmasked, valves are diﬃ  cult to visualise on chest 
radiographs and this maintained masking of physicians 
and patients alike if they underwent investigations for a 
clinical deterioration in the absence of a pneumothorax.
The study was undertaken at a single centre with 
experience in bronchoscopic procedures and in selecting 
patients for lung volume reduction. Therefore, it shows 
the results that are possible. However, for these results to 
be generalisable, it will require the establishment of a 
similar clinical infrastructure, and as with any new 
technique, there is likely to be a learning curve as it is 
implemented.
In some patients, ideal positioning of the valves is not 
possible due to patient anatomy (eg, insuﬃ  cient length 
of bronchus to place the valve adequately leading to early 
expectoration, or diﬃ  cult access to a particular segment), 
which might aﬀ ect the eﬀ ectiveness of valves as a 
treatment strategy. The present study was not suﬃ  ciently 
large for this to be an issue but we recommend in future 
studies that a bronchoscopic assessment of the technical 
feasibility of valve placement be included in the protocol. 
It remains the case that LVRS is an eﬀ ective treatment in 
upper lobe predominant bullous emphysema regardless 
of ﬁ ssure integrity.
Further work is needed to establish how this technique 
should best be deployed relative to LVRS2,3 and other 
developing techniques, such as lung volume reduction 
coils9 and bronchoscopic thermal vapour ablation.29 Most 
importantly, there is a considerable overlap between the 
indications for BLVR and LVRS, and thus a stepwise 
approach with bronchoscopic techniques considered at 
an earlier stage to defer, prevent, or act as a bridge to 
LVRS could be appropriate. Alternatively, LVRS might be 
the deﬁ nitive treatment that should be oﬀ ered earlier. 
Prospective trials comparing LVRS and valve placement 
will be needed to clarify this.
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